[1]杜习智△,赵成龙,秦玉花,等.奥沙利铂与卡铂治疗中晚期非小细胞肺癌的meta分析[J].郑州大学学报(医学版),2015,(04):550-554.
 DU Xizhi,ZHAO Chenglong,QIN Yuhua,et al.Metaanalysis of oxaliplatin versus carboplatin based chemotherapy in treatment of advanced NSCLC[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2015,(04):550-554.
点击复制

奥沙利铂与卡铂治疗中晚期非小细胞肺癌的meta分析()
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2015年04期
页码:
550-554
栏目:
应用研究
出版日期:
2015-07-20

文章信息/Info

Title:
Metaanalysis of oxaliplatin versus carboplatin based chemotherapy in treatment of advanced NSCLC
作者:
杜习智△赵成龙秦玉花赵红卫
河南省人民医院药学部 郑州 450003
Author(s):
DU Xizhi ZHAO Chenglong QIN Yuhua ZHAO Hongwei
Department of Pharmacy, Henan Provincial Peoples Hospital, Zhengzhou 450003
关键词:
奥沙利铂卡铂非小细胞肺癌meta分析
Keywords:
soxaliplatin carboplatin NSCLC metaanalysis
分类号:
R734.2
文献标志码:
A
摘要:
目的:系统评价奥沙利铂联合化疗与卡铂联合化疗治疗中晚期非小细胞肺癌(NSCLC)的有效性和安全性。方法:检索Medline、Cochrane Library、PubMed、EMbase、CNKI、CBM、VIP和WANFANG数据库,收集关于奥沙利铂联合化疗与卡铂联合化疗治疗中晚期NSCLC的随机对照试验(RCT),采用RevMan 5.1进行meta分析。结果:最终纳入6个RCT,共784例患者。Meta分析显示,两个方案的客观缓解率(OR=0.82,95%CI:0.60~1.14)、客观控制率(OR=0.97,95%CI:0.72~1.31)、ⅢⅣ度恶心、呕吐发生率(OR=1.02,95%CI: 0.55~1.91)差异无统计学意义,而奥沙利铂联合方案ⅢⅣ度贫血(OR=0.18,95%CI:0.05~0.63)、ⅢⅣ度白细胞减少(OR=0.29,95%CI:0.15~0.57)、ⅢⅣ度中性粒细胞减少(OR=0.41,95%CI:0.28~0.61)、ⅢⅣ度血小板减少(OR=0.20,95%CI:0.05~0.71)的发生率较卡铂联合方案明显降低,神经毒性的发生率明显升高(OR=30.58,95%CI:7.17~130.38)。结论:奥沙利铂联合化疗方案治疗中晚期NSCLC疗效与卡铂联合化疗方案相似,但安全性更好。
Abstract:
Aim: To determine the efficacy and toxicity of oxaliplatin based chemotherapy versus carboplatin based chemotherapy for advanced nonsmall cell lung cancer(NSCLC). Methods: The randomized controlled trials(RCTs) on oxaliplatin based chemotherapy versus carboplatin based chemotherapy for advanced NSCLC were searched in Medline, the Cochrane Library, PubMed, EMbase, CNKI, CBM, VIP and WANFANG Data base. A metaanalysis was carried out by RevMan 5.1.Results: Six trials that included a total of 784 patients were analyzed. The metaanalysis demonstrated that, compared with the carboplatin based chemotherapy, oxaliplatin based chemotherapy could decrease the risks of hematological toxicity, including grade 3-4 anemia(OR=0.18, 95%CI:0.05-0.63), grade 3-4 leukopenia(OR=0.29, 95%CI:0.15-0.57), grade 3-4 neutropenia (OR=0.41, 95%CI:0.28-0.61), and grade 3-4 thrombocytopenia(OR=0.20, 95%CI:0.05-0.71), but increase the risk of neurotoxicity(OR=30.58, 95%CI:7.17-130.38). There were no significant differences between the two groups in overall response rate(OR=0.82, 95%CI:0.60-1.14), disease control rate(OR=0.97, 95%CI:0.72-1.31), or grade 34 nausea and vomiting(OR=1.02, 95%CI:0.55-1.91). Conclusion: Oxaliplatin based chemotherapy has similar efficacy to carboplatin based chemotherapy, but milder toxicity.

参考文献/References:

[1]Cataldo VD,Gibbons DL,PerezSoler R,et al.Treatment of nonsmallcell lung cancer with erlotinib or gefitinib[J].N Engl J Med,2011,364(10):947
[2]Peters S,Adjei AA,Gridelli C,et al.Metastatic nonsmallcell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and followup[J].Ann Oncol,2012,23(Suppl 7):vii56
[3]赵成龙,赵红卫,柴东燕,等.2012年河南省人民医院200例肿瘤患者化疗药应用合理性分析[J].中国医院用药评价与分析,2013,13(11):983
[4]Bidoli P,Zilembo N,Cortinovis D,et al.Randomized phase Ⅱ threearm trial with three platinumbased doublets in metastatic nonsmallcell lung cancer:an Italian trials in medical oncology study[J].Ann Oncol,2007,18(3):461
[5]Scagliotti GV,Kortsik C,Dark GG,et al.Pemetrexed combined with oxaliplatin or carboplatin as firstline treatment in advanced nonsmall cell lung cancer a multicenter, randomized, phase Ⅱ trial[J].Clinical Cancer Research,2005,11(2):690
[6]Weissman CH,Reynolds CH,Neubauer MA,et al.A phase Ⅲ randomized trial of gemcitabineoxaliplatin versus carboplatinpaclitaxel as firstline therapy in patients with advanced nonsmall cell lung cancer[J].J Thorac Oncol,2011,6(2):358
[7]葛敏,彭海鹰.多西紫杉醇联合奥沙利铂治疗晚期非小细胞肺癌临床分析[J].河北医药,2008,30(11):1704
[8]敬秀清.多西他赛联合奥沙利铂或卡铂治疗晚期非小细胞肺癌的近期疗效观察[J].中国医药指南,2012,10(19):26
[9]刘震天,陈颖兰.长春瑞宾联合顺铂、卡铂、奥沙利铂在治疗晚期非小细胞肺癌的比较[J].实用临床医学,2006,7(10):61
[10]Piché N,Leblond FA,Sidéris L,et al.Rationale for heating oxaliplatin for the intraperitoneal treatment of peritoneal carcinomatosis: a study of the effect of heat on intraperitoneal oxaliplatin using a murine model[J].Ann Surg,2011,254(1):138

相似文献/References:

[1]周云△.替尼泊苷和5氟尿嘧啶联合奥沙利铂或顺铂治疗晚期胃癌疗效对比[J].郑州大学学报(医学版),2009,(05):957.
 ZHOU Yun.Comparison of regimen VOF and VCF in treatment of advanced gastric cancer[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2009,(04):957.
[2]常方方,高明,周云#.奥沙利铂联合顺铂对体外培养BGC823细胞增殖及Bcl2、Bax、Caspase3蛋白表达的影响[J].郑州大学学报(医学版),2009,(02):359.
 CHANG Fangfang,GAO Ming,ZHOU Yun.Effects of OXA and DDP on cell proliferation and Bcl2,Bax,Caspase3 expression of BGC823 cells in vitro[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2009,(04):359.
[3]李杨)),李艳华),樊青霞),等.硫酸镁联合葡萄糖酸钙预防奥沙利铂神经毒性25例[J].郑州大学学报(医学版),2009,(04):897.
[4]侯新芳△,刘莺,刘文静,等.奥沙利铂联合替加氟治疗老年晚期食管癌35例[J].郑州大学学报(医学版),2010,(04):547.
[5]杨晓利),王峰),夏金),等.替吉奥或卡培他滨联合奥沙利铂一线治疗晚期结直肠癌效果对比分析[J].郑州大学学报(医学版),2013,(05):687.
 YANG Xiaoli),WANG Feng),XIA Jin),et al.Retrospective study on S1 plus oxaliplatin versus capecitabine plus oxaliplatin for firstline treatment of patients with advanced colorectal cancer[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2013,(04):687.

更新日期/Last Update: 1900-01-01